Skip Navigation
Skip to contents

JPTM : Journal of Pathology and Translational Medicine


Author index

Page Path
HOME > Articles and issues > Author index
Ji Yeol Lee 1 Article
Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma
Woo Jin Oh, Arthur Minwoo Chung, Jee Soon Kim, Ji Heun Han, Sung Hoo Hong, Ji Yeol Lee, Yeong Jin Choi
J Pathol Transl Med. 2016;50(5):345-354.   Published online August 7, 2016
  • 9,611 View
  • 288 Download
  • 22 Citations
AbstractAbstract PDF
The pathologic distinction between high-grade prostate adenocarcinoma (PAC) involving the urinary bladder and high-grade urothelial carcinoma (UC) infiltrating the prostate can be difficult. However, making this distinction is clinically important because of the different treatment modalities for these two entities.
A total of 249 patient cases (PAC, 111 cases; UC, 138 cases) collected between June 1995 and July 2009 at Seoul St. Mary’s Hospital were studied. An immunohistochemical evaluation of prostatic markers (prostate-specific antigen [PSA], prostate-specific membrane antigen [PSMA], prostate acid phosphatase [PAP], P501s, NKX3.1, and α-methylacyl coenzyme A racemase [AMACR]) and urothelial markers (CK34βE12, p63, thrombomodulin, S100P, and GATA binding protein 3 [GATA3]) was performed using tissue microarrays from each tumor.
The sensitivities of prostatic markers in PAC were 100% for PSA, 83.8% for PSMA, 91.9% for PAP, 93.7% for P501s, 88.3% for NKX 3.1, and 66.7% for AMACR. However, the urothelial markers CK34βE12, p63, thrombomodulin, S100P, and GATA3 were also positive in 1.8%, 0%, 0%, 3.6%, and 0% of PAC, respectively. The sensitivities of urothelial markers in UC were 75.4% for CK34βE12, 73.9% for p63, 45.7% for thrombomodulin, 22.5% for S100P, and 84.8% for GATA3. Conversely, the prostatic markers PSA, PSMA, PAP, P501s, NKX3.1, and AMACR were also positive in 9.4%, 0.7%, 18.8%, 0.7%, 0%, and 8.7% of UCs, respectively.
Prostatic and urothelial markers, including PSA, NKX3.1, p63, thrombomodulin, and GATA3 are very useful for differentiating PAC from UC. The optimal combination of prostatic and urothelial markers could improve the ability to differentiate PAC from UC pathologically.


Citations to this article as recorded by  
  • Metastatic prostate cancer presenting as a posterior mediastinal mass: A rare presentation
    Muhammad Haider, Arun Umesh Mahtani, Bachar Botrus, Foma Munoh Kenne, Madiha Fatima Master
    Clinical Case Reports.2023;[Epub]     CrossRef
  • Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component
    Simone de Brot, Jennifer Lothion‐Roy, Llorenç Grau‐Roma, Emily White, Franco Guscetti, Mark A. Rubin, Nigel P. Mongan
    Veterinary and Comparative Oncology.2022; 20(1): 38.     CrossRef
  • Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications
    Arsalan Tariq, Amy E. McCart Reed, Andrew Morton, Sima Porten, Ian Vela, Elizabeth D. Williams, John W. Yaxley, Peter C. Black, Matthew J. Roberts
    European Urology Focus.2022; 8(5): 1256.     CrossRef
  • Immunohistochemical Reactivity of Prostate-Specific Membrane Antigen in Salivary Gland Tumors
    Haruto Nishida, Yoshihiko Kondo, Takahiro Kusaba, Hiroko Kadowaki, Tsutomu Daa
    Head and Neck Pathology.2022; 16(2): 427.     CrossRef
  • Weak NKX3.1 expression in a urothelial carcinoma: A diagnostic pitfall
    Maryam Abdo, Robert Hoyt, Ashley Highfill, Daniel Mettman
    Human Pathology Reports.2022; 27: 300599.     CrossRef
  • Gene of the month: NKX3.1
    Jon Griffin, Yuqing Chen, James W F Catto, Sherif El-Khamisy
    Journal of Clinical Pathology.2022; 75(6): 361.     CrossRef
  • Diagnostic Value of GATA3 and Uroplakin 3 in Differentiating Urothelial Carcinoma from Prostatic and Colorectal Carcinoma
    Maha Salama, Dina A. Khairy
    Open Access Macedonian Journal of Medical Sciences.2022; 10(A): 514.     CrossRef
  • Diagnostic challenges for the distinction of high-grade prostatic adenocarcinoma and high-grade urothelial carcinoma of simultaneous occurrences - A literature review
    Shreyas Bhushan Jayade, Manana Jikurashvili
    GEORGIAN SCIENTISTS.2022;[Epub]     CrossRef
  • Cytomorphology, immunoprofile, and clinicopathologic correlation of metastatic prostatic carcinoma
    Xiaoqi Lin, Qiuying Shi, Ximing J. Yang
    Human Pathology.2022; 130: 36.     CrossRef
  • Cutaneous Metastasis of Prostate Adenocarcinoma: A Rare Presentation of a Common Disease
    Alexander Dills, Okechukwu Obi, Kevin Bustos, Jesse Jiang, Shweta Gupta
    Journal of Investigative Medicine High Impact Case Reports.2021; 9: 232470962199076.     CrossRef
  • Mining The Cancer Genome Atlas gene expression data for lineage markers in distinguishing bladder urothelial carcinoma and prostate adenocarcinoma
    Ewe Seng Ch’ng
    Scientific Reports.2021;[Epub]     CrossRef
  • Immunohistochemical analysis of thrombomodulin expression in myocardial tissue from autopsy cases of ischemic heart disease
    Takeshi Kondo, Motonori Takahashi, Gentaro Yamasaki, Marie Sugimoto, Azumi Kuse, Mai Morichika, Kanako Nakagawa, Makoto Sakurada, Migiwa Asano, Yasuhiro Ueno
    Legal Medicine.2021; 51: 101897.     CrossRef
  • Application and Pitfalls of Immunohistochemistry in Diagnosis of Challenging Genitourinary Cases
    Jenny Ross, Guangyuan Li, Ximing J. Yang
    Archives of Pathology & Laboratory Medicine.2020; 144(3): 290.     CrossRef
  • New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers
    Karin Ried, Tasnuva Tamanna, Sonja Matthews, Peter Eng, Avni Sali
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • An Unlikely Culprit: Gastric Metastasis from Primary Prostatic Adenocarcinoma
    Eric Omar Then, Spoorthi Nutakki, Andrew Ofosu, Saad Saleem, Vijay Gayam, Tagore Sunkara, Vinaya Gaduputi
    Journal of Gastrointestinal Cancer.2020; 51(3): 1081.     CrossRef
  • MRI of prostatic urethral mucinous urothelial carcinoma: Expanding the differential diagnosis for T2 hyperintense prostatic masses
    Neel Patel, Bryan R. Foster, Elena K. Korngold, Kyle Jensen, Kevin R. Turner, Fergus V. Coakley
    Clinical Imaging.2020; 68: 68.     CrossRef
  • Morphological and Immunohistochemical Biomarkers in Distinguishing Prostate Carcinoma and Urothelial Carcinoma: A Comprehensive Review
    Francesca Sanguedolce, Davide Russo, Vito Mancini, Oscar Selvaggio, Beppe Calò, Giuseppe Carrieri, Luigi Cormio
    International Journal of Surgical Pathology.2019; 27(2): 120.     CrossRef
  • A Case of Metastatic Prostate Cancer to the Urethra That Resolved After Androgen Deprivation Therapy
    Darren J. Bryk, Kenneth W. Angermeier, Eric A. Klein
    Urology.2019; 129: e4.     CrossRef
  • The Homeodomain Transcription Factor NKX3.1 Modulates Bladder Outlet Obstruction Induced Fibrosis in Mice
    Mehul S. Patel, Diana K. Bowen, Nicholas M. Tassone, Andrew D. Gould, Kirsten S. Kochan, Paula R. Firmiss, Natalie A. Kukulka, Megan Y. Devine, Belinda Li, Edward M. Gong, Robert W. Dettman
    Frontiers in Pediatrics.2019;[Epub]     CrossRef
  • Cancer of unknown primary: Ancillary testing of cytologic and small biopsy specimens in the era of targeted therapy
    Morgan L. Cowan, Christopher J. VandenBussche
    Cancer Cytopathology.2018; 126(S8): 724.     CrossRef
  • Glandular Tumors of the Urachus and Urinary Bladder: A Practical Overview of a Broad Differential Diagnosis
    Alexander S. Taylor, Rohit Mehra, Aaron M. Udager
    Archives of Pathology & Laboratory Medicine.2018; 142(10): 1164.     CrossRef
  • S100P as a Marker for Urothelial Histogenesis: A Critical Review and Comparison With Novel and Traditional Urothelial Immunohistochemical Markers
    Moushumi Suryavanshi, Julian Sanz-Ortega, Deepika Sirohi, Mukul K. Divatia, Chisato Ohe, Claudia Zampini, Daniel Luthringer, Steven C. Smith, Mahul B. Amin
    Advances in Anatomic Pathology.2017; 24(3): 151.     CrossRef

JPTM : Journal of Pathology and Translational Medicine